← All trials
NCT01594346
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2000
- Primary completion
- Apr 1, 2010
- Completion date
- Apr 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 349
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- State of New YorkLead sponsor
- University of California, San DiegoStudy director
- Columbia UniversityStudy director
- National Institute on Aging (NIA)Collaborator
- National Center for Complementary and Integrative Health (NCCIH)Collaborator
- University of California, San DiegoCollaborator
- Columbia UniversityCollaborator
- National Institutes of Health (NIH)Collaborator
- Department of Veteran AffairsStudy director
- Department of Veteran AffairsCollaborator
- State of New YorkReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.